Literature DB >> 16613924

Verteporfin photodynamic therapy induced apoptosis in choroidal neovascular membranes.

K Petermeier1, O Tatar, W Inhoffen, M Völker, B A Lafaut, S Henke-Fahle, F Gelisken, F Ziemssen, S Bopp, K U Bartz-Schmidt, S Grisanti.   

Abstract

AIM: To evaluate the impact of verteporfin photodynamic therapy (PDT) on the induction of apoptosis in choroidal neovascular membranes (CNV) secondary to age related macular degeneration.
METHODS: Retrospective review of 22 surgically excised CNV. 12 of these patients had been treated with PDT 3-146 days previously. Apoptotic cells were detected with the TUNEL technique and compared to the expression of CD34 (endothelial cells, EC), CD105 (activated endothelial cells), Ki-67 (proliferation marker), and cytokeratin18 (retinal pigment epithelial cells, RPE).
RESULTS: CNV excised 3 days after PDT were characterised both by collapsed and patent vessels. The EC displayed a statistical significant positive TUNEL reaction when compared to the remaining treated CNV (p < 0.001) and untreated CNV (P = 0.002). The proliferative activity was reduced. CNV excised 1-5 months after PDT displayed a patent vascularisation and high proliferative activity. All membranes either treated or untreated disclosed only sporadic TUNEL positive cells within the stroma and the RPE.
CONCLUSIONS: Verteporfin PDT leads to selective and effective damage of EC within CNV. Both patent and occluded vessels were lined by apoptotic EC. This finding and the increased expression of proliferation marker at later time points suggest that revascularisation after PDT is caused by angiogenesis rather than recanalisation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16613924      PMCID: PMC1857222          DOI: 10.1136/bjo.2006.090852

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  20 in total

Review 1.  Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration.

Authors:  U Schmidt-Erfurth; T Hasan
Journal:  Surv Ophthalmol       Date:  2000 Nov-Dec       Impact factor: 6.048

2.  Clinicopathologic studies of age-related macular degeneration with classic subfoveal choroidal neovascularization treated with photodynamic therapy.

Authors:  N G Ghazi; N M Jabbour; Z C De La Cruz; W R Green
Journal:  Retina       Date:  2001       Impact factor: 4.256

3.  Apoptosis induction by the photosensitizer verteporfin: identification of mitochondrial adenine nucleotide translocator as a critical target.

Authors:  A S Belzacq; E Jacotot; H L Vieira; D Mistro; D J Granville; Z Xie; J C Reed; G Kroemer; C Brenner
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

4.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1999-10

5.  Histological findings of surgically excised choroidal neovascular membranes after photodynamic therapy.

Authors:  U E Schnurrbusch; K Welt; L C Horn; P Wiedemann; S Wolf
Journal:  Br J Ophthalmol       Date:  2001-09       Impact factor: 4.638

6.  Consequences of verteporfin photodynamic therapy on choroidal neovascular membranes.

Authors:  Olcay Tatar; Edwin Kaiserling; Annemarie Adam; Faik Gelisken; Kei Shinoda; Michael Völker; Bart A Lafaut; Karl Ulrich Bartz-Schmidt; Salvatore Grisanti
Journal:  Arch Ophthalmol       Date:  2006-06

7.  Photodynamic effects on choroidal neovascularization and physiological choroid.

Authors:  Ursula Schmidt-Erfurth; Stephan Michels; Irene Barbazetto; Horst Laqua
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-03       Impact factor: 4.799

8.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.

Authors: 
Journal:  Am J Ophthalmol       Date:  2001-05       Impact factor: 5.258

9.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.

Authors:  N M Bressler
Journal:  Arch Ophthalmol       Date:  2001-02

10.  Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes.

Authors:  Ursula Schlötzer-Schrehardt; Arne Viestenz; Gottfried O H Naumann; Horst Laqua; S Michels; Ursula Schmidt-Erfurth
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2002-08-27       Impact factor: 3.117

View more
  4 in total

1.  Effect of verteporfin photodynamic therapy on endostatin and angiogenesis in human choroidal neovascular membranes.

Authors:  Olcay Tatar; Kei Shinoda; Annemarie Adam; Tillmann Eckert; Claus Eckardt; Klaus Lucke; Christoph Deuter; Karl Ulrich Bartz-Schmidt; Salvatore Grisanti
Journal:  Br J Ophthalmol       Date:  2006-09-20       Impact factor: 4.638

2.  Matrix metalloproteinases in human choroidal neovascular membranes excised following verteporfin photodynamic therapy.

Authors:  Olcay Tatar; Annemarie Adam; Kei Shinoda; Tillmann Eckert; Gábor B Scharioth; Micheal Klein; Efdal Yoeruek; Karl Ulrich Bartz-Schmidt; Salvatore Grisanti
Journal:  Br J Ophthalmol       Date:  2007-05-02       Impact factor: 4.638

3.  Age-related macular degeneration: current treatments.

Authors:  Jean Pierre Hubschman; Shantan Reddy; Steven D Schwartz
Journal:  Clin Ophthalmol       Date:  2009-06-02

4.  Vascular regrowth following photodynamic therapy in the chicken embryo chorioallantoic membrane.

Authors:  Patrycja Nowak-Sliwinska; Judy R van Beijnum; Maaike van Berkel; Hubert van den Bergh; Arjan W Griffioen
Journal:  Angiogenesis       Date:  2010-09-15       Impact factor: 9.596

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.